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Acute viral bronchiolitis in young infants remains a cause of 
substantial morbidity and health care costs. It is the most common 
lower respiratory tract condition and the most common reason for 
the hospitalization of infants. A number of respiratory viruses have 
been associated with acute viral bronchiolitis although respiratory 
syncytial virus (RSV) remains the most frequently identified virus. 
The majority of affected infants have a mild self-limiting disease, 
while others have more severe illness and require hospitalization 
and,sometimes,ventilatory support. Bronchiolitis has an overall 
mortality rate of 0.2-0.5%, with 99% of deaths occurring in de-
veloping countries.
Bronchiolitis is a clinical diagnosis based on a typical pattern of 
rhinorrhoea, cough, poor feeding, tachypnoea, subcostal recession 
and auscultatory findings of wheezing and fine inspiratory crack-
les. There is a distinct seasonal pattern with a peak in incidences 
in autumn and winter.
Evidence-based reviews have suggested a limited role for 
diagnostic laboratory or radiographic tests in typical cases of 
bronchiolitis. A nasopharyngeal aspirate has been identified as 
the most sensitive methodfor virus detection. Pulse oximetry also 
provides valuable information about the severity of the disease and 
guides subsequent management.
Supportive therapy remains the major treatment option, as no 
other specific treatments to date haveshown to provide clinically 
significantbenefits. Minimal handling, oxygen supplementation, 
and appropriate fluid management (including nasogastric feeds 
if necessary) are the mainstay of therapy. Nasal suctioning can be 
helpful as well. Very young infants may require cardiopulmonary 
monitoring for apnoea. There is a wide variation in treatment for 
bronchiolitis, which has led to the development of evidence-based 
clinical practice guidelines for treatment. Bronchodilators are in-
consistently used and have been advocated for certain subgroups 
of infants. Several large, recent trials have revealed a lack of ef-
ficacy for routine use of either bronchodilators or corticosteroids 
for the treatment of bronchiolitis. Preliminary evidence suggests 
a potential future role nebulized hypertonic saline.
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The study was aimed to evaluate the role of the specific serolo-
gic diagnosis of Mycoplasma infection and clinical peculiarities of 
bronchopulmonary diseases with recurrent episodes of wheezing 
in children. 
Seventy-six children (ages 6 months to 7 years) with wheezing 
disorders (bronchial asthma and obstructive bronchitis) were 
included in our study. The diagnosis, classification of asthma, 
and asthma severity levels were based on GINA guidelines. The 
determination of M. pneumonia and M. hominis IgG, IgA, IgM 
antibodies were performed by using an enzyme-linked immuno-
sorbent assay (Human, Germania).
Analysis of the serologic examination results showed that 56 
patients had the Mycoplasma infection and 20 exhibited no signs of 
Mycoplasma infection. In I group (the Mycoplasma-positive group) 
4 patients had bronchial asthma, and 6 patients with obstructi-
ve bronchitis had specific antibodies in diagnostic titers (IgM 
0,35±0,01 (cut-off 0,25), IgG 0,33±0,13 (cut-off 0,30±0,03) and 
IgA 1,47±0,01 (cut-off 0,801), IgG 1,18±0,46 (cut-off 0,33±0,02) 
accordingly). In the remainder of the first group (47 children), 10 
children had b\ronchial asthma and 36 children had obstructive 
bronchitis associated with acute pneumonia. Levels of specific 
antibodies consisted of: M. pneumonia (4 children) IgM 0,29±0,02 
(cut-off 0,25), IgG 0,47±0,02 (cut-off 0,32) and M. hominis (4 
children) IgA 0,25±0,15 (cut-off 0,24), IgG 1,03±0,25; cut-off 
0,3±0,01 and in 2 children a mix infection (M. hominis and M. 
pneumonia IgG 0,80±0,2 (cut-off 0,28) and IgG 0,50±0,07 (cut-off 
0,33) accordingly) (in the group with pneumonia and bronchial 
asthma) and M. pneumonia 0,45±0,06 (cut-off 0,34), IgG 0,44±0,02 
(cut-off 0,35) and M. hominis IgM 0,34±0,09 (cut-off 0,30), IgG 
0,97±0,17 (cut-off 0,29) (in the group with pneumonia and ob-
structive bronchitis). 
In II group (the Mycoplasma-negative group) 4 patients had 
obstructive bronchitis and 16 children had pneumonia, including 
6 children with associated bronchial asthma and 10 patients had 
pneumonia with obstructive bronchitis. The levels of specific 
antibodies was below the cut-off: M. pneumonia IgM 0,18±0,09 
(cut-off 0,52±0,15), IgG 0,17±0,02 (cut-off 0,33±0,03), M. pneu-
moniae IgM 0,1±0,02 (cut-off 0,25), IgG 0,14±0,02 (cut-off 0,27) 
and in last group IgM 0,1±0,04 (cut-off 0,25) and IgG 0,17±0,04 
(cut-off 0,29) accordingly. 
